

Registered number:
OC413389

Abby Pharma (U.K) LLP
Unaudited Accounts
for the Period
24 August 2016 to 31 August 2017

Abby Pharma (U.K) LLP
Balance Sheet
as at 31 August 2017

	2017
	£
Current Assets	
Debtors	1,101,325
Cash at bank and in hand	316,637
	1,417,962
Creditors falling due within one year	(426,649)
Net Current Assets / (Liabilities)	991,313
Net Assets Attributable to Members	991,313
Represented by:	
Loans and other debts due to members within one year	
Members' capital classified as a liability	891,393
	891,393
Members' other interests	
Members' capital classified as a equity	99,920
	991,313
Total members' interests	
Loans and other debts due to members	891,393
Members' other interests	99,920
	991,313

Abby Pharma (U.K) LLP
Balance Sheet
as at 31 August 2017

These accounts have been prepared and delivered in accordance with the provisions applicable to LLPs subject to the small LLPs regime.

The members have not delivered a copy of the LLP's Profit and Loss account as permitted by s444(5A) of the Companies Act 2006 (as applied to LLPs).

The members acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 (as applied to LLPs) with respect to accounting records and the preparation of accounts.

For the period ended 31 August 2017 the LLP was entitled to exemption under section 477 of the Companies Act 2006 (as applied to LLPs) relating to small LLPs.

The financial statements were approved by the members and signed on their behalf by:

.....

Approved by members on 24 May 2018

Ultrasure Company Inc

Designated Member

Abby Pharma (U.K) LLP

Registered number: OC413389 (England and Wales)

1. Accounting Policies

Basis of preparation

The financial statements are prepared under the historical cost convention and the Statement of Recommended Practice "Accounting by Limited Liability Partnerships" issued in July 2014.

These financial statements reflect the results of the LLP for the period ended 31 August 2017.

Turnover

Turnover represents amounts due in respect of trade during the period, including contracts agreed on but unpaid at the end of the period. The company is involved in the commercialisation of pharmaceutical products and related consultancy work.

Tax provisions

Taxation on the profits of the LLP is solely the liability of individual members. Therefore, neither income tax nor deferred tax arising in respect of the LLP's profit is included in these financial statements.

2. Members' Interests

	Members capital classed as equity	Other reserve	Total 2017
	£	£	£
Brought Forward	-	-	-
Profit (loss) for period available for discretionary division among members	-	891,393	891,393
Members' interest after profit (loss) for period	-	891,393	891,393
Other divisions of profits (losses)	-	-	-
Introduced by members	99,920	-	99,920
Balance carried forward	99,920	891,393	991,313

3. Other Information

The profit and loss is determined using estimates of the recoverability of amounts invoiced. The accounts are compiled on the assumption that the company is a going concern.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.